Analyst Research

Report Title Price
Thomson Reuters Stock Report - UNITED THERAPEUTICS CORPORATION (UTHR-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Market Edge Equity Research Report
Provider: Market Edge
$10.00
Buy
UNITED THERAPEUTICS CP (UTHR) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy
United Therapeutics Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

United Therapeutics Corp Reaffirms FY 2013 Revenue Guidance


Tuesday, 26 Feb 2013 06:00am EST 

United Therapeutics Corp reaffirmed fiscal 2013 revenue guidance and continue to expect revenues to fall within a range of 5% above or below $1 billion. 

Latest Developments for United Therapeutics Corp

Latest Key Developments in Biotechnology

Company Quote

United Therapeutics Corp
(UTHR.OQ)
67.82
-0.65 -0.95%
22 May 2013